| Filed On | Filing |
|---|---|
| 27 Sep 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On September 23, 2024, Caribou Biosciences, Inc. (the “Company”) designated Ryan Fischesser, the Company’s current Vice President of Finance and Controller, as the Company’s interim principal financial officer and interim principal accou... |
| 14 Jul 2023 |
8-K/A: Other Events
ANTLER Phase 1 trial results summary Transformative genome-edited therapies for patients July 13, 2023 |
| 23 Sep 2022 |
8-K/A: Submission of Matters to a Vote of Security Holders
On September 20, 2022, Caribou Biosciences, Inc. (the “Company”) held its annual meeting of stockholders (the "Annual Meeting"). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual ... |
| 18 Jul 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On May 11, 2022, Caribou Biosciences, Inc. (the “Company”) filed a Current Report on Form 8-K under Item 5.02 pursuant to which it announced that the Board of Directors (the “Board”) of the Company had elected David L. Johnson, M.B.A., t... |
Loading...
